Suchergebnisse - "Anna C Pavlick"

Andere Suchmöglichkeiten:
c pavlick » c patrick (Erweiterte Suche)

1

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series

von: Paul T. Finger

2019, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
2

A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.

von: Patrick A Ott

2010, in: PLoS ONE

Wird geladen...
3

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

von: Michael Lattanzi

2018, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
4

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.

von: Molly Yancovitz

2012, in: PLoS ONE

Wird geladen...
5

Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma

von: Guilherme Rabinowits

2021, in: JID Innovations

Wird geladen...
6

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

von: Michael F. Gowen

2018, in: Journal of Translational Medicine

Wird geladen...
7

A phase II trial of sorafenib in metastatic melanoma with tissue correlates.

von: Patrick A Ott

2010, in: PLoS ONE

Wird geladen...
8

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer

von: Christopher A Barker

2022, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
9

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

von: Omid Hamid

2023, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
10

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

von: Ryan J. Sullivan

2018, in: Journal for ImmunoTherapy of Cancer

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!